Article Text

Download PDFPDF
First line treatment with colchicine reduced recurrent pericarditis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with recurrent pericarditis, does the addition of colchicine to conventional therapy with aspirin or prednisone reduce recurrence better than conventional therapy alone?

Clinical impact ratings IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Cardiology ★★★★★☆☆


Embedded ImageDesign

randomised controlled trial (COlchicine for REcurrent pericarditis [CORE] trial).

Embedded ImageAllocation


Embedded ImageBlinding

blinded {data collectors, outcome assessors, monitoring committee, and data analysts}†.*

Embedded ImageFollow up period

mean 20 months (range 8–44 mo).

Embedded ImageSetting

a hospital in Torino, Italy.

Embedded ImagePatients

84 patients ⩾18 years of age (mean age 54 y, 65% women) who had a first recurrence of pericarditis and previous idiopathic, viral, and autoimmune causes of the first episode of acute pericarditis. Exclusion criteria were tuberculous, neoplastic, or purulent causes of the first episode; severe liver disease or transaminase concentrations >1.5 times the upper limit of …

View Full Text


  • * See glossary.

  • For correspondence: Dr M Imazio, Maria Vittoria Hospital, Torino, Italy. massimo_imazio{at}

  • Source of funding: not stated.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd